1,2 Isolates of S. pyogenes are universally susceptible to penicillin and consequently few laboratories routinely perform susceptibility testing with this organism. In Europe, the prevalence of macrolide resistance among S. pyogenes rose from 10.4% in 2002 -03 to 11.6% in 2004 -05. 3 Similarly, in the USA, the Centers for Disease Control and Prevention provided national surveillance data that reported a gradual trend of increasing macrolide resistance of S. pyogenes from 4% to 5% in 1996 -98 to 8% to 9% in 1999 -2001 while 99.5% of isolates remained susceptible to clindamycin. 4 Like S. pyogenes, S. agalactiae remains fully susceptible to penicillin. However, erythromycin and erythromycin/clindamycin resistance of S. agalactiae have been reported to be 22% and 6%, respectively.
Sir, b-Haemolytic streptococci, especially Streptococcus pyogenes and Streptococcus agalactiae, are frequently responsible for a diverse range of clinical manifestations, from mild skin/soft tissue infections and pharyngitis to more serious diseases, such as bacteraemia, cellulitis, puerperal sepsis, meningitis, pneumonia and necrotizing fasciitis. 1, 2 Isolates of S. pyogenes are universally susceptible to penicillin and consequently few laboratories routinely perform susceptibility testing with this organism. In Europe, the prevalence of macrolide resistance among S. pyogenes rose from 10.4% in 2002 -03 to 11.6% in 2004 -05. 3 Similarly, in the USA, the Centers for Disease Control and Prevention provided national surveillance data that reported a gradual trend of increasing macrolide resistance of S. pyogenes from 4% to 5% in 1996 -98 to 8% to 9% in 1999 -2001 while 99.5% of isolates remained susceptible to clindamycin. 4 Like S. pyogenes, S. agalactiae remains fully susceptible to penicillin. However, erythromycin and erythromycin/clindamycin resistance of S. agalactiae have been reported to be 22% and 6%, respectively. 5 Iclaprim is a novel diaminopyrimidine inhibitor within the same class as trimethoprim but with more potent and bactericidal in vitro activity against major Gram-positive pathogens in complicated skin and soft tissue infections (cSSTIs), including Staphylococcus aureus, S. pyogenes and S. agalactiae. 6 An intravenous formulation of iclaprim has completed Phase III trials for cSSTIs. In addition, Phase II trials of iclaprim administered by intravenous infusion for patients with hospital-acquired and ventilator-associated pneumonia and of an oral formulation of iclaprim as step-down therapy for patients with cSSTIs are ongoing. 6 Considering the importance of such streptococci in the aetiology of cSSTIs and the emergence of resistance to several clinically used antibiotics, the current study was designed to investigate the in vitro activity of iclaprim and comparators against S. pyogenes and S. agalactiae, the key causative pathogens in cSSTIs.
The in vitro activities of iclaprim (Arpida AG, Reinach, Switzerland), trimethoprim/sulfamethoxazole (1:19 ratio), clarithromycin, clindamycin, linezolid, penicillin G, levofloxacin and vancomycin were investigated against 500 S. pyogenes and 44 S. agalactiae. Isolates tested were non-repeat isolates collected during 2006 -07 from clinical material including respiratory and wound infections from hospitals in 10 European countries. MIC determinations were carried out using CLSI broth microdilution methodology with cation-adjusted Mueller-Hinton broth supplemented with 5% (v/v) lysed horse blood. 7 Summary MIC data are presented in Table 1 . Iclaprim exhibited potent activity against all S. pyogenes isolates. When comparing the MIC 90 of iclaprim and comparators, iclaprim (MIC 90 0.06 mg/L) was 16 times more active than co-trimoxazole (MIC 90 1 mg/L) and levofloxacin (MIC 90 1 mg/L), 32 times more active than linezolid (MIC 90 2 mg/L) and 8 times more active Table 1 . Activity of iclaprim and comparators against S. pyogenes and S. agalactiae Trimethoprim and its 1:19 combination with sulfamethoxazole, co-trimoxazole, have been used extensively in clinical practice for more than 40 years. Although co-trimoxazole is often used for the treatment of cSSTIs, it is often considered ineffective for infections due to S. pyogenes. 8 In contrast, in two Phase III clinical trials of cSSTIs, iclaprim exhibited good eradication rates for S. pyogenes. 9, 10 Considering the importance of b-haemolytic streptococcal species in the aetiology of cSSTIs and the emergence of resistance to several clinically used antibiotics, 1 -4 these data further demonstrate the potential for iclaprim to treat infections caused by S. pyogenes and S. agalactiae in cSSTIs.
